Status:
UNKNOWN
Effect of Atorvastatin on Subclinical Atherosclerosis
Lead Sponsor:
Dr Cipto Mangunkusumo General Hospital
Conditions:
CMV
Eligibility:
All Genders
20-45 years
Phase:
NA
Brief Summary
Statin administration is supposed to reduce subclinical atherosclerosis by decreasing LDL cholesterol levels, possibly via lipid-independent anti-inflammatory effect. Its pleiotropic properties also a...
Detailed Description
Extended description of the protocol, including more technical information
Eligibility Criteria
Inclusion
- Ages between 20 to 45 years old
- Using stable ART at least 1 year
- Positive IgG CMV
- Viral load HIV RNA \<50 copies / ml
Exclusion
- Undergoing hepatitis C DAA therapy
- Decompensated cirrhosis or acute liver failure
- History of coronary artery disease
- Diabetes mellitus
- History of of brain infection, epilepsy, stroke
- History of rhabdomyolysis or myopathy
- Pregnant or breastfeeding
- Severe depression
- Using statin therapy in the past 6 weeks
- History of statin hypersensitivity
- Framingham Risk Score above 10% within LDL ≥130
- Framingham Risk Score under 10% within LDL ≥160
- Out of Periodontitis Index (Upper right molars, top series, upper left molars, lower right molars, bottom series, lower left molars)
Key Trial Info
Start Date :
September 30 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 15 2021
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT04101136
Start Date
September 30 2019
End Date
July 15 2021
Last Update
January 29 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cipto Mangunkusumo General Hospital
Jakarta, Center Jakarta, Indonesia, 10340